Enliven Therapeutics (ELVN) Competitors $19.92 +0.90 (+4.73%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$19.95 +0.03 (+0.15%) As of 09/18/2025 04:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELVN vs. MENS, ACLX, PCVX, KRYS, ARWR, ACAD, ADMA, AAPG, MTSR, and MIRMShould you be buying Enliven Therapeutics stock or one of its competitors? The main competitors of Enliven Therapeutics include Jyong Biotech (MENS), Arcellx (ACLX), Vaxcyte (PCVX), Krystal Biotech (KRYS), Arrowhead Pharmaceuticals (ARWR), ACADIA Pharmaceuticals (ACAD), ADMA Biologics (ADMA), Ascentage Pharma Group International (AAPG), Metsera (MTSR), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry. Enliven Therapeutics vs. Its Competitors Jyong Biotech Arcellx Vaxcyte Krystal Biotech Arrowhead Pharmaceuticals ACADIA Pharmaceuticals ADMA Biologics Ascentage Pharma Group International Metsera Mirum Pharmaceuticals Jyong Biotech (NASDAQ:MENS) and Enliven Therapeutics (NASDAQ:ELVN) are both pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk. Does the media refer more to MENS or ELVN? In the previous week, Jyong Biotech had 5 more articles in the media than Enliven Therapeutics. MarketBeat recorded 10 mentions for Jyong Biotech and 5 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 1.00 beat Jyong Biotech's score of 0.45 indicating that Enliven Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jyong Biotech 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enliven Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, MENS or ELVN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJyong BiotechN/AN/AN/AN/AN/AEnliven TherapeuticsN/AN/A-$89.02M-$2.00-9.96 Do institutionals & insiders hold more shares of MENS or ELVN? 95.1% of Enliven Therapeutics shares are held by institutional investors. 25.9% of Enliven Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is MENS or ELVN more profitable? Jyong Biotech's return on equity of 0.00% beat Enliven Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Jyong BiotechN/A N/A N/A Enliven Therapeutics N/A -29.15%-27.88% Do analysts rate MENS or ELVN? Enliven Therapeutics has a consensus target price of $41.20, suggesting a potential upside of 106.83%. Given Enliven Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Enliven Therapeutics is more favorable than Jyong Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Enliven Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryEnliven Therapeutics beats Jyong Biotech on 6 of the 9 factors compared between the two stocks. Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELVN vs. The Competition Export to ExcelMetricEnliven TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.13B$2.55B$5.78B$10.27BDividend YieldN/A57.29%5.74%4.64%P/E Ratio-9.9623.4276.5226.98Price / SalesN/A721.36546.03182.41Price / CashN/A169.7137.1760.63Price / Book3.145.4313.886.37Net Income-$89.02M$32.95M$3.29B$271.46M7 Day Performance-0.20%2.04%1.60%2.53%1 Month Performance0.81%8.20%6.89%9.42%1 Year Performance-13.65%-2.34%82.40%30.16% Enliven Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELVNEnliven Therapeutics2.8792 of 5 stars$19.92+4.7%$41.20+106.8%-8.5%$1.13BN/A-9.9650High Trading VolumeMENSJyong BiotechN/A$51.82-15.7%N/AN/A$4.68BN/A0.0031High Trading VolumeACLXArcellx2.1367 of 5 stars$75.20-1.3%$114.31+52.0%-0.7%$4.23B$107.94M-21.9980PCVXVaxcyte2.2404 of 5 stars$31.00-3.6%$106.25+242.7%-72.0%$4.18BN/A-7.54160Positive NewsGap UpKRYSKrystal Biotech4.9534 of 5 stars$155.71+8.4%$209.00+34.2%-12.1%$4.16B$359.21M31.65210High Trading VolumeARWRArrowhead Pharmaceuticals4.164 of 5 stars$28.67-3.5%$43.14+50.5%+51.6%$4.11B$3.55M-22.40400Trending NewsInsider TradeAnalyst RevisionGap UpACADACADIA Pharmaceuticals4.2949 of 5 stars$24.67+4.5%$29.65+20.2%+51.6%$3.98B$957.80M18.55510ADMAADMA Biologics3.5475 of 5 stars$15.30-5.0%$27.67+80.8%-16.4%$3.84B$426.45M17.79530Positive NewsAAPGAscentage Pharma Group InternationalN/A$38.63-4.5%N/AN/A$3.77B$134.35M0.00600MTSRMetseraN/A$34.21-4.1%$63.50+85.6%N/A$3.75BN/A0.0081Positive NewsMIRMMirum Pharmaceuticals3.1472 of 5 stars$74.19-0.2%$74.44+0.3%+98.7%$3.73B$429.16M-61.31140 Related Companies and Tools Related Companies Jyong Biotech Competitors Arcellx Competitors Vaxcyte Competitors Krystal Biotech Competitors Arrowhead Pharmaceuticals Competitors ACADIA Pharmaceuticals Competitors ADMA Biologics Competitors Ascentage Pharma Group International Competitors Metsera Competitors Mirum Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELVN) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELVN Stock Alerts